Evidence map›Paper›PMID 29430172›Full record

ArticleDrug design, development and therapy2018

Dysregulation of Neuregulin-1/ErbB signaling in the hippocampus of rats after administration of doxorubicin.

Dehua Liao, Yujin Guo, Daxiong Xiang, Ruili Dang, Pengfei Xu, Hualin Cai, Lizhi Cao, Pei Jiang

Open access · goldAbstract read
In one paragraph

Article in Drug design, development and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Dehua LiaoDepartment of Pharmacy, Hunan Cancer Hospital.
Yujin GuoDepartment of Pharmacy, Jining First People's Hospital, Jining Medical University, Jining, People's Republic of China.
Daxiong XiangDepartment of Pharmacy, Institute of Clinical Pharmacy & Pharmacology, Second Xiangya Hospital, Central South University, Changsha.
Ruili DangDepartment of Pharmacy, Jining First People's Hospital, Jining Medical University, Jining, People's Republic of China.
Pengfei XuDepartment of Pharmacy, Jining First People's Hospital, Jining Medical University, Jining, People's Republic of China.
Hualin CaiDepartment of Pharmacy, Institute of Clinical Pharmacy & Pharmacology, Second Xiangya Hospital, Central South University, Changsha.
Lizhi CaoDepartment of Pharmacy, Hunan Cancer Hospital.
Pei JiangDepartment of Pharmacy, Jining First People's Hospital, Jining Medical University, Jining, People's Republic of China.
Central South University · CNJining First People's Hospital · CNHunan Cancer Hospital · CNJining Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveLong-term use of doxorubicin (Dox) can cause neurobiological side effects associated with depression, but the underlying mechanisms remain equivocal. While recent evidence has indicated that Neuregulin-1 (NRG1) and its ErbB receptors play an essential role in neural function, much is still unknown concerning the biological link between the NRG1/ErbB pathway and the Dox-induced neurotoxicity. Therefore, we examined the protein expression of NRG1 and ErbB receptors in the hippocampus of rats following Dox treatment. MATERIALS AND

methodsThe drug was administered every 2 days at a dose of 2.5 mg/kg, and the animals in different groups were treated with intraperitoneal injection for three or seven times, respectively.

resultsOur data showed that the rats treated with Dox for seven times (DoxL group) exhibited depression-like behaviors, whereas the short-term treatment (DoxS group) had no effect on the behavioral changes. Dox treatment also induced the neural apoptosis with more severe neurotoxicity. Intriguingly, the expression of NRG1 and the ratio of pErbB4/ErbB4 and pErbB2/ErbB2 were significantly decreased in the DoxL group, but enhanced activation of ErbB receptors was observed in the DoxS group. In parallel, administration of Dox for seven times suppressed the downstream Akt and ERK phosphorylation, while the Akt phosphorylation was enhanced with the administration of Dox for three times.

conclusionOur data first showed the Dox-induced alterations of the NRG1/ErbB system in the hippocampus, indicating the potential involvement of the NRG1/ErbB pathway in the Dox-induced nervous system dysfunction.

Indexed as

AnimalsAntibiotics, AntineoplasticApoptosisBehavior, AnimalDoxorubicinDrug Administration ScheduleErb-b2 Receptor Tyrosine KinasesExtracellular Signal-Regulated MAP KinasesHippocampusInjections, IntraperitonealMaleNeuregulin-1Neurotoxicity SyndromesPhosphorylationProto-Oncogene Proteins c-aktRats, Sprague-DawleyAntibiotics, AntineoplasticDoxorubicinErbb2 protein, ratErb-b2 Receptor Tyrosine KinasesErbb4 protein, ratExtracellular Signal-Regulated MAP KinasesNeuregulin-1Nrg1 protein, ratProto-Oncogene Proteins c-aktReceptor, ErbB-4AktchemotherapydepressionERKneurotoxicityNRG1/ErbB system

Identifiers

PMID29430172
PMCPMC5796460
OpenAlexW2788042917

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.